PRIME Scheme Evaluation: Insights from Enhanced...

By HEOR Staff Writer

March 19, 2026

The PRIME Scheme Evaluation of the European Medicines Agency’s (EMA) PRIority Medicines (PRIME), launched in 2016, confirms early and enhanced regulatory support accelerates medicines for unmet needs. A two-year pilot (April 2023–March 2025) teste...
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Ago...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
FDA Biosimilar Approval Reforms: Accelerating Access and Reducing Drug Costs
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review